Clinical trials: Colorectal Cancer Metastatic to Liver
Pancreatic Cancer, Colorectal Cancer
GLP-1 RA Plus SOC Treatment in First-line, Metastatic Pancreatic, Colorectal, or Hepatocellular Cancer
There is a growing number of patients diagnosed with gastrointestinal cancers who are also simultaneously being treated with GLP-1 Receptor Agonists (RA)s.
- Conditions
- Pancreatic Cancer, Colorectal Cancer, Hepatocellular Carcinoma
- Trial name
- NCT07627191
- Testing
- GLP1-RA (semaglutide)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- University of Arizona
Colorectal Cancer, Liver Metastases
Metastatic Colorectal Cancer Liver Metastases Outcomes After Resin 90Y Microsphere Radioembolization in the USA Evaluation Project
Investigator initiated multi-institutional retrospective review of clinical and radiographic outcomes after 90Y resin microsphere radioembolization for metastatic colorectal liver metastases in the USA.
- Trial name
- MORE (NCT01815879)
- Where
- United States
- Volunteers
- 1,000 people
- Sponsor
- Andrew Kennedy
Colorectal Cancer, Liver Metastases
Multimodal Assessment of Liver Volume and Function
In liver surgery peroperative assessment och the future liver remnant (FLR) is pivotal in order to avoid posthepatectomy liver failure. To date this is mainly performed by measuring the volume of the FLR.
- Trial name
- NCT03140917
- Testing
- Multimodal liver function assessment
- Where
- Sweden
- Volunteers
- 10 people
- Sponsor
- Karolinska University Hospital
Colorectal Cancer, Resectable Liver Metastasis
Phase 3 Study of Surgery Combined With Neoadjuvant Chemotherapy(XELOX) in Colorectal Cancer With Resectable Liver Metastasis
This study aims to discuss the efficacy and safety of neoadjuvant chemotherapy with XELOX regimen (oxaliplatin plus capecitabine) .
- Trial name
- NCT00630045
- Testing
- neoadjuvant chemotherapy with oxaliplatin and capecitabine, resection of liver metastasis
- Where
- 2 sites in China
- Volunteers
- 392 people
- Sponsor
- Peking University People's Hospital
Colorectal Cancer With Non Resectable Hepatic Metastasis
Intra-arterial Hepatic Beads Loaded With Irinotecan With Concomitant Chemotherapy With FOLFOX in Patients With Colorectal Cancer With Unresectable Liver Metastases: a Phase II Multicenter Study
Treatment of patients with colorectal cancer having liver metastases is currently based on systemic chemotherapy. Triple therapy with 5FU, oxaliplatin and irinotecan intravenously was effective in terms of response and secondary…
- Trial name
- NCT01839877
- Testing
- HIA DEBIRI + systemic FOLFOX
- Where
- 9 sites in France
- Volunteers
- 58 people
- Sponsor
- Federation Francophone de Cancerologie Digestive
Liver Only Metastasis From KRAS Exon 2 Wild Type (Under Protocol 1.0-1.2 Edition) and RAS Wild Type (Under Protocol 2.0 Edition) Colorectal Cancer
Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases
The purpose of this study is to evaluate efficacy and safety of mFOLFOX6+bevacizumab and mFOLFOX6+cetuximab for liver only metastasis from KRAS Exon 2 wild type (under protocol 1.0-1.2 edition) and RAS wild type (under protocol…
- Trial name
- ATOM (NCT01836653)
- Testing
- Bevacizumab, Cetuximab, L-OHP
- Where
- Japan
- Volunteers
- 122 people
- Sponsor
- EPS Corporation
Colorectal Cancer, Liver Metastasis
Feasibility Study of Neoadjuvant Chemotherapy Modified FOLFOX6 for Resectable Liver Metastases of Colorectal Cancers
The purpose of this study is to evaluate the safety of liver resection for metastatic, resectable lesions from colorectal cancers after systemic chemotherapy.
- Trial name
- NCT00594529
- Testing
- Surgery
- Where
- Japan
- Volunteers
- 27 people
- Sponsor
- Kyoto University
Colorectal Cancer, Liver Metastases
ALPPS Versus PVE/PL
Study Title Comparison of two different models of liver growth stimulation in advanced colorectal liver metastatic disease, (LIGRO Trial) enabling liver resection Methodology Scandinavian Multiple Center Randomized Registry Based…
- Trial name
- LIGRO (NCT02215577)
- Testing
- In-situ split, Portal embolization or ligation
- Where
- 7 sites in Denmark, Norway and 1 more
- Volunteers
- 100 people
- Sponsor
- Regionalt Cancercentrum Väst
Anal Cancer, Anxiety Disorder
Psychological and Emotional Impact in Patients Undergoing Treatment For Metastatic Cancer Either in a Clinical Trial or as Standard Off-Trial Therapy
RATIONALE: Gathering information from patients who received treatment for metastatic cancer while participating in a phase II or phase III randomized clinical trial and from patients receiving standard treatment off-trial may…
- Conditions
- Anal Cancer, Anxiety Disorder, Breast Cancer, Depression
- Trial name
- NCT00896467
- Testing
- questionnaire administration, psychosocial assessment and care, quality-of-life assessment
- Where
- 2 sites in France
- Volunteers
- 200 people
- Sponsor
- Centre Oscar Lambret
Metastatic Colorectal Cancer
Conversion From Unresectable To Resectable Metastatic Colorectal Cancer.
Most patients with mCRC are treated with palliative chemotherapy and only a small number of patients with limited metastatic disease achieve long-term remission following metastasectomy.
- Trial name
- CONVERSION (NCT03401294)
- Testing
- FOLFOXIRI and Bevacizumab
- Where
- Canada
- Volunteers
- 32 people
- Sponsor
- University of Saskatchewan
Unresectable Colorectal Liver Metastases
Yttrium-90 Carbon Microspheres in Patients With Unresectable Colorectal Liver Metastases
To evaluate the efficacy and safety of yttrium-90 carbon microspheres in patients with unresectable colorectal liver metastases
- Trial name
- NRT-uCRLM (NCT05692037)
- Testing
- Selective internal radiation therapy (SIRT) with yttrium-90 carbon microspheres
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Zhongda Hospital
Metastatic Colorectal Cancer
Study to Determine the Efficacy of Regorafenib in Metastatic Colorectal Cancer Patients and to Discover Biomarkers
In recent years, anti-angiogenic agents have been incorporated into clinical practice for the treatment of metastatic CRC, leading to improvements in progression-free survival and overall survival.
- Trial name
- NCT01949194
- Testing
- Regorafenib
- Where
- 5 sites in Canada
- Volunteers
- 48 people
- Sponsor
- Gerald Batist
Liver Metastasis
Pringle Manoeuvre Versus Portal Vein Clamping for Liver Resection
Liver resection is an operation to remove the diseased part of the liver. The liver is supplied by two vessels, the hepatic artery and the portal vein supplying 25% and 75% respectively of the total blood flow with 50% oxygen…
- Trial name
- NCT02042794
- Where
- United Kingdom
- Volunteers
- 80 people
- Sponsor
- The Leeds Teaching Hospitals NHS Trust
Colorectal Adenocarcinoma Metastatic in the Liver
Validation of the Classification for Resectability and Ablatability Criteria for the Treatment of Liver Only Colorectal Metastases
The aim of this study is to validate a proposed classification system regarding overall survival as well as a comparison with patients with liver metastases and extrahepatic metastasis of colorectal cancer.
- Trial name
- NCT07569341
- Testing
- Liver resection
- Where
- Sweden
- Volunteers
- 116 people
- Sponsor
- University Hospital, Linkoeping
Colorectal Liver Metastases
TRANsplantation vs reSECTion After Conversion Therapy for Initially Unresectable Colorectal Liver Metastases
The TRANSECT trial is a prospective randomized study designed to evaluate the role of liver transplantation (LT) versus radical local treatment (hepatic resection and/or ablation) in patients with initially unresectable…
- Trial name
- TRANSECT (NCT07607873)
- Testing
- Liver Transplantation, Liver Resection plus Ablation
- Where
- Italy
- Volunteers
- 70 people
- Sponsor
- Niguarda Hospital
Immunotherapy, Colorectal Cancer
TAS-102 Combined With Bevacizumab and Tislelizumab Third-line or Above in the Treatment of Liver Metastasis in Colorectal Cancer
To evaluate the clinical efficacy and safety of TAS-102 combined with bevacizumab and tislelizumab in third-line or above treatment in patients with advanced colorectal adenocarcinoma with liver metastasis.
- Trial name
- NCT05314101
- Testing
- Tislelizumab, bevacizumab, TAS-102
- Where
- China
- Volunteers
- 25 people
- Sponsor
- Fujian Cancer Hospital
Secondary Malignant Neoplasm of Liver
A Trial on SBRT Versus MWA for Inoperable Colorectal Liver Metastases (CLM)
The trial is designed to perform a rigorous evaluation of efficacy and tolerability of SBRT by means of a randomised, controlled trial in patients affected by inoperable colorectal liver metastases. The chosen comparator is MWA.
- Trial name
- NCT02820194
- Testing
- Stereotactic Body Radiation Therapy, Microwave Ablation
- Where
- Italy
- Volunteers
- 26 people
- Sponsor
- Istituto Clinico Humanitas
Colorectal Cancer Metastatic
Chemotherapy Alone Versus Chemotherapy Plus Targeted Therapy as Adjuvant Therapy for Initially Unresectable Colorectal Cancer Liver Metastases
Chemotharapy plus targeted therapy regimen, as an adjuvant therapy, can effectively reduce the rate of both intrahepatic and extrahepatic recurrence in initially unresectable CRLM patients.
- Trial name
- NCT06027775
- Testing
- Targeted agent
- Volunteers
- 198 people
- Sponsor
- Fudan University
Colorectal Cancer
Fruquintinib Plus Camrelizumab and HAIC in the Treatment of Non-MSI-H Advanced Colorectal Cancer
Liver metastasis is the main cause of death in patients with colorectal cancer. The treatment of liver metastasis of colorectal cancer is the key to prolong the survival of patients.
- Trial name
- NCT06423937
- Testing
- combination therapy Combination: Fruquintinib plus Camrelizumab and HAIC (TOMOX/TOMIRI) Maintenance: Fruquintinib plus Camrelizumab
- Where
- China
- Volunteers
- 129 people
- Sponsor
- Fudan University
Metastatic Colon Cancer, Liver Cancer
Hepatic Artery Infusion (HAI) Program at Duke University
The Duke HAI program was implemented in November 2018 and treated 30 patients in its first 17 months using the Medtronic Synchromed II device (only commercially available device suitable for HAI for cancer patients).
- Conditions
- Metastatic Colon Cancer, Liver Cancer, Intrahepatic Cholangiocarcinoma
- Trial name
- NCT04511793
- Testing
- Medtronic Synchromed II pump
- Sponsor
- Michael Lidsky, M.D.